Evaluation of database-derived pathway development for enabling biomarker discovery for hepatotoxicity

Biomarkers in Medicine

Volumn 8, Issue 2, 2014, Pages 185-200

  Hebels, Dennie Ga ^a   Jetten, Marlon J A ^a   Aerts, Hugo J W ^b   Herwig, Ralf ^c   Theunissen, Daniël H J ^a   Gaj, Stan ^a   Van Delft, Joost H ^a   Kleinjans, Jos C S ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

'omics databases; biomarker; DILI; diXa; drug induced liver injury; hepatotoxicity; over representation analysis; pathway development; text mining databases; toxicogenomics

Indexed keywords

BIOLOGICAL MARKERS; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; GENE EXPRESSION PROFILING; HUMANS; LIVER; TOXICOGENETICS; TRANSCRIPTOME;

EID: 84894344424     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.154     Document Type: Review

References (93)

1. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin. Liver Dis. 11(3), 477-505 (2007).
2. Stirnimann G, Kessebohm K, Lauterburg B. Liver injury caused by drugs: an update. Swiss Med. Wkly 140, w13080 (2010).
3. Tarantino G, Di Minno MN, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J. Gastroerentol. 15(23), 2817-2833 (2009).
4. Bjornsson E. Drug-induced liver injury: Hys rule revisited. Clin. Pharmacol. Ther. 79(6), 521-528 (2006).
5. Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment. Pharmacol. Ther. 25(10), 1135-1151 (2007).
6. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin. Liver Dis. 22(2), 169-183 (2002).
7. Galan MV, Potts JA, Silverman AL, Gordon SC. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected]. J. Clin. Gastroenterol. 39(1), 64-67 (2005).
8. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 10(8), 1018-1023 (2004).
9. Sgro C, Clinard F, Ouazir K et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36(2), 451-455 (2002).
10. Larson AM, Polson J, Fontana RJ et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42(6), 1364-1372 (2005).
11. Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: Summary of a workshop. Hepatology 47(4), 1401-1415 (2008).
12. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr. Med. Chem. 16(23), 3041-3053 (2009).
13. Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Handb. Exp. Pharmacol. (196), 369-405 (2010).
14. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin. Liver Dis. 29(4), 337-347 (2009).
15. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. Hepatology 33(4), 1009-1013 (2001).
16. Lee WM. Drug-induced hepatotoxicity. N. Engl. J. Med. 349(5), 474-485 (2003).
17. Dambach DM, Andrews BA, Moulin F. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. 33(1), 17-26 (2005).
18. Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137(12), 947-954 (2002).
19. Ghabril M, Chalasani N, Bjornsson E. Drug-induced liver injury: a clinical update. Curr. Opin. Gastroenterol. 26(3), 222-226 (2010).
20. Fromenty B. Drug-induced liver injury in obesity. J. Hepatol. 58(4), 824-826 (2013).
21. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 287(17), 2215-2220 (2002).
22. Andrade RJ, Camargo R, Lucena MI, Gonzalez-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert Opin. Drug Saf. 3(4), 329-344 (2004).
23. Andrade RJ, Robles M, Fernandez-Castaner A, Lopez-Ortega S, Lopez-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J. Gastroerentol. 13(3), 329-340 (2007).
24. Egan WJ, Zlokarnik G, Grootenhuis PDJ. In silico prediction of drug safety: despite progress there is abundant room for improvement. Drug Discov. Today Technol. 1(4), 381-387 (2004).
25. Greaves P, Williams A, Eve M. First dose of potential new medicines to humans: how animals help. Nat. Rev. Drug Discov. 3(3), 226-236 (2004).
26. Metushi IG, Nakagawa T, Uetrecht J. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats. Chem. Res. Toxicol. 25(11), 2567-2576 (2012).
27. Metushi IG, Uetrecht J. Lack of liver injury in Wistar rats treated with the combination of isoniazid and rifampicin. Mol. Cell. Biochem. doi:10.1007/s11010-013-1864-7 (2013) (Epub ahead of print).
28. Olson H, Betton G, Robinson D et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32(1), 56-67 (2000).
29. Olson H, Betton G, Stritar J, Robinson D. The predictivity of the toxicity of pharmaceuticals in humans from animal data - an interim assessment. Toxicol. Lett. 102-103, 535-538 (1998).
30. Shih H, Pickwell GV, Guenette DK, Bilir B, Quattrochi LC. Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Hum. Exp. Toxicol. 18(2), 95-105 (1999).
31. Suter L, Schroeder S, Meyer K et al. EU framework 6 project: predictive toxicology (PredTox) - overview and outcome. Toxicol. Appl. Pharmacol. 252(2), 73-84 (2011).
32. Uetrecht J. Role of animal models in the study of drug-induced hypersensitivity reactions. AAPS J. 7(4), e914-e921 (2005).
33. Van Summeren A, Renes J, van Delft JH, Kleinjans JC, Mariman EC. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. Toxicol. In Vitro 26(3), 373-385 (2012).
34. Au JS, Navarro VJ, Rossi S. Review article: drug-induced liver injury - its pathophysiology and evolving diagnostic tools. Aliment. Pharmacol. Ther. 34(1), 11-20 (2011).
35. Casciano DA. The use of genomics in model in vitro systems. Adv. Exp. Med. Biol. 745, 210-220 (2012).
36. Przybylak KR, Cronin MT. In silico models for drug-induced liver injury - current status. Expert Opin. Drug Metab. Toxicol. 8(2), 201-217 (2012).
37. van Meer S, de Man RA, Siersema PD, van Erpecum KJ. Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies. World J. Gastroerentol. 19(40), 6744-6756 (2013).
38. Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin. Liver Dis. 26(1), 42-51 (2006).
39. Aithal GP, Watkins PB, Andrade RJ et al. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 89(6), 806-815 (2011).
40. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 141(5), 1572-1585 (2011).
41. Davis AP, Murphy CG, Johnson R et al. The Comparative Toxicogenomics Database: update 2013. Nucleic Acids Res. 41(Database issue), D1104-D1114 (2013).
42. Mattingly CJ, Colby GT, Forrest JN, Boyer JL. The Comparative Toxicogenomics Database (CTD). Environ. Health Perspect. 111(6), 793-795 (2003).
43. Buchkremer S, Hendel J, Krupp M et al. Library of molecular associations: curating the complex molecular basis of liver diseases. BMC Genomics 11, 189 (2010).
44. Rappaport N, Nativ N, Stelzer G et al. MalaCards: an integrated compendium for diseases and their annotation. Database (Oxford) 2013, bat018 (2013).
45. Stelzer G, Dalah I, Stein TI et al. In-silico human genomics with GeneCards. Hum. Genomics 5(6), 709-717 (2011).
46. Barrett T, Edgar R. Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol. 411, 352-369 (2006).
47. Brazma A, Parkinson H, Sarkans U et al. ArrayExpress - a public repository for microarray gene expression data at the EBI. Nucleic Acids Res. 31(1), 68-71 (2003).
48. Aff S, Dominguez M, Lozano JJ et al. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut 62(3), 452-460 (2013).
49. Andersen JB, Spee B, Blechacz BR et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142(4), 1021-1031.e15 (2012).
50. Bourd-Boittin K, Bonnier D, Leyme A et al. Protease profiling of liver fibrosis reveals the ADAM metallopeptidase with thrombospondin type 1 motif, 1 as a central activator of transforming growth factor beta. Hepatology 54(6), 2173-2184 (2011).
51. Caillot F, Hiron M, Goria O et al. Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients. Am. J. Pathol. 175(1), 46-53 (2009).
52. Lake AD, Novak P, Fisher CD et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 39(10), 1954-1960 (2011).
53. Liu W, Baker SS, Baker RD, Nowak NJ, Zhu L. Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. PLoS ONE 6(9), e24363 (2011).
54. Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT. Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker. PLoS ONE 8(3), e59459 (2013).
55. Nissim O, Melis M, Diaz G et al. Liver regeneration signature in hepatitis B virus (HBV)-Associated acute liver failure identified by gene expression profiling. PLoS ONE 7(11), e49611 (2012).
56. Onomoto K, Morimoto S, Kawaguchi T et al. Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. PLoS ONE 6(5), e19799 (2011).
57. Rasmussen AL, Tchitchek N, Susnow NJ et al. Early transcriptional programming links progression to hepatitis C virus-induced severe liver disease in transplant patients. Hepatology 56(1), 17-27 (2012).
58. Sia D, Hoshida Y, Villanueva A et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144(4), 829-840 (2013).
59. Starmann J, Falth M, Spindelbock W et al. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS ONE 7(10), e46584 (2012).
60. Staten NR, Welsh EA, Sidik K et al. Multiplex transcriptional analysis of paraffin-embedded liver needle biopsy from patients with liver fibrosis. Fibrogenesis Tissue Repair 5(1), 21 (2012).
61. Wurmbach E, Chen YB, Khitrov G et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45(4), 938-947 (2007).
62. Shannon P, Markiel A, Ozier O et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13(11), 2498-2504 (2003).
63. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27(3), 431-432 (2011).
64. Salomonis N, Hanspers K, Zambon AC et al. GenMAPP 2: new features and resources for pathway analysis. BMC Bioinformatics 8, 217 (2007).
65. van Iersel MP, Kelder T, Pico AR et al. Presenting and exploring biological pathways with PathVisio. BMC Bioinformatics 9, 399 (2008).
66. Uehara T, Ono A, Maruyama T et al. The Japanese toxicogenomics project: application of toxicogenomics. Mol. Nutr. Food Res. 54(2), 218-227 (2010).
67. Ma MK, Woo MH, Mcleod HL. Genetic basis of drug metabolism. Am. J. Health Syst. Pharm. 59(21), 2061-2069 (2002).
68. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev. 41(2), 89-295 (2009).
69. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-Approved drug labeling for the study of drug-induced liver injury. Drug Discov. Today 16(15-16), 697-703 (2011).
70. Brandon EF, Raap CD, Meijerman I, Beijnen JH, Schellens JH. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol. Appl. Pharmacol. 189(3), 233-246 (2003).
71. Gomez-Lechon MJ, Castell JV, Donato MT. An update on metabolism studies using human hepatocytes in primary culture. Expert Opin. Drug Metab. Toxicol. 4(7), 837-854 (2008).
72. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr. Drug Metab. 5(5), 443-462 (2004).
73. Guillouzo A. Liver cell models in in vitro toxicology. Environ. Health Perspect. 106(Suppl. 2), 511-532 (1998).
74. Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, Omiecinski CJ. Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol. Appl. Pharmacol. 222(1), 42-56 (2007).
75. Guo L, Dial S, Shi L et al. Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab. Dispos. 39(3), 528-538 (2011).
76. Hart SN, Li Y, Nakamoto K, Subileau EA, Steen D, Zhong XB. A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab. Dispos. 38(6), 988-994 (2010).
77. Jetten MJ, Kleinjans JC, Claessen SM, Chesne C, van Delft JH. Baseline and genotoxic compound induced gene expression profiles in HepG2 and HepaRG compared with primary human hepatocytes. Toxicol. In Vitro 27(7), 2031-2040 (2013).
78. Parkinson A, Kazmi F, Buckley DB, Yerino P, Ogilvie BW, Paris BL. System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes. Drug Metab. Pharmacokinet. 25(1), 16-27 (2010).
79. Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab. Dispos. 31(8), 1035-1042 (2003).
80. Gerets HH, Tilmant K, Gerin B et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol. Toxicol. 28(2), 69-87 (2012).
81. Li AP. Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem. Biol. Interact. 168(1), 16-29 (2007).
82. Gao J, Ade AS, Tarcea VG et al. Integrating and annotating the interactome using the MiMI plugin for cytoscape. Bioinformatics 25(1), 137-138 (2009).
83. Jayapandian M, Chapman A, Tarcea VG et al. Michigan Molecular Interactions (MiMI): putting the jigsaw puzzle together. Nucleic Acids Res. 35(Database issue), D566-D571 (2007).
84. Tarcea VG, Weymouth T, Ade A et al. Michigan molecular interactions r2: from interacting proteins to pathways. Nucleic Acids Res. 37(Database issue), D642-D646 (2009).
85. Kelder T, van Iersel MP, Hanspers K et al. WikiPathways: building research communities on biological pathways. Nucleic Acids Res. 40(Database issue), D1301-D1307 (2012).
86. Abdel-Bakky MS, Hammad MA, Walkerit LA, Ashfaqi MK. Developing and characterizing a mouse model of hepatotoxicity using oral pyrrolizidine alkaloid (monocrotaline) administration, with potentiation of the liver injury by co-Administration of LPS. Nat. Prod. Commun. 5(9), 1457-1462 (2010).
87. De Bruyn T, Chatterjee S, Fattah S et al. Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity. Expert Opin. Drug Metab. Toxicol. 9(5), 589-616 (2013).
88. Doktorova TY, Yildirimman R, Vinken M et al. Transcriptomic responses generated by hepatocarcinogens in a battery of liver-based in vitro models. Carcinogenesis 34(6), 1393-1402 (2013).
89. Hill A, Mesens N, Steemans M, Xu JJ, Aleo MD. Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development. Drug Metab. Rev. 44(1), 127-140 (2012).
90. Kostadinova R, Boess F, Applegate D et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 268(1), 1-16 (2013).
91. Lake BG, Price RJ. Evaluation of the metabolism and hepatotoxicity of xenobiotics utilizing precision-cut slices. Xenobiotica 43(1), 41-53 (2013).
92. Pery AR, Brochot C, Zeman FA et al. Prediction of dose-hepatotoxic response in humans based on toxicokinetic/toxicodynamic modeling with or without in vivo data: a case study with acetaminophen. Toxicol. Lett. 220(1), 26-34 (2013).
93. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Expert Opin. Drug Saf. 13(1), 67-81 (2013).